Anzeige
Mehr »
Freitag, 10.07.2026 - Börsentäglich über 12.000 News
483 Gramm Gold pro Tonne! Diese Gold-Aktie hat zwei Asse im Ärmel
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
228 Leser
Artikel bewerten:
(0)

Point of Care Diagnostics Market worth $31.46 billion by 2031 | MarketsandMarkets

DELRAY BEACH, Fla., July 10, 2026 /PRNewswire/ -- According to MarketsandMarkets, the Point of Care Diagnostics Market is projected to grow from about USD 20.63 billion in 2026 to USD 31.46 billion by 2031, at a CAGR of 8.8%.

Browse 250 market data Tables and 100 Figures spread through 300 Pages and in-depth TOC on 'Point of Care Diagnostics Market - Global Forecast to 2031'

Point of Care Diagnostics Market Size & Forecast:

  • Market Size Available for Years: 2025-2031
  • 2026 Market Size: USD 20.63 billion
  • 2031 Projected Market Size: USD 31.46 billion
  • CAGR (2026-2031): 8.8%

Point of Care Diagnostics Market Trends & Insights:

  • The glucose monitoring products segment held 34.8% of the market in 2025.
  • In 2025, the home care settings and self-testing market was valued at USD 6,936.5 million.
  • China is expected to register the highest CAGR of 11.1% during the forecast period.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=106829185

The increasing global burden of diabetes, cardiovascular diseases, infectious diseases, respiratory illnesses, and chronic kidney disorders is significantly expanding the adoption of POC diagnostics. These conditions require rapid and accurate diagnosis to enable timely clinical intervention, making point-of-care testing an essential component of modern healthcare delivery. The growing aging population, increasing demand for decentralized healthcare, and rising need for faster clinical decision-making are further accelerating market growth. Healthcare providers are increasingly adopting blood glucose monitoring systems, rapid infectious disease tests, cardiac biomarker assays, blood gas and electrolyte analyzers, coagulation testing, HbA1c testing, and molecular point-of-care platforms to improve diagnostic efficiency, reduce turnaround time, and support better patient outcomes. The expansion of testing across hospitals, emergency departments, physician offices, retail clinics, pharmacies, and home healthcare settings further strengthens this trend. As healthcare systems continue to emphasize early diagnosis, decentralized care, and personalized medicine, demand for POC diagnostics is expected to grow steadily, driving continued expansion of the global market.

Glucose monitoring products accounted for the largest share of the global point-of-care diagnostics market in 2025.

The segment's dominance is primarily driven by the high global burden of diabetes, which requires regular blood glucose monitoring across hospitals, clinics, diagnostic centers, pharmacies, and home-care settings. The increasing adoption of point-of-care blood glucose meters and continuous glucose monitoring (CGM)-enabled testing solutions supports rapid clinical decision-making, effective glycemic management, and improved patient outcomes. Growing awareness of diabetes prevention and self-management, coupled with the expanding aging population and rising incidence of lifestyle-related diseases, continues to boost demand for glucose monitoring products. In addition, technological advancements, including smartphone-connected glucose meters, improved biosensor accuracy, cloud-based data integration, and minimally invasive monitoring technologies, are enhancing testing convenience and accuracy. Favorable reimbursement policies, continuous product innovation, and expanding diabetes screening and management programs across developed and emerging markets further strengthen the segment's leading position, enabling glucose monitoring products to maintain the highest market value among all point-of-care diagnostics product categories in 2025.

Request Sample Pages @https://www.marketsandmarkets.com/requestsampleNew.asp?id=106829185

Clinical laboratories accounted for the largest share of the global point-of-care diagnostics market in 2025.

The dominance of clinical laboratories is driven by their central role in delivering high-volume diagnostic testing with rapid and reliable results across a broad range of diseases. Clinical laboratories are widely used for point-of-care testing for infectious diseases, glucose monitoring, cardiometabolic disorders, coagulation, and other routine diagnostic applications, making them the primary end users of point-of-care diagnostic products. The growing prevalence of chronic and infectious diseases, increasing demand for early disease detection, and rising diagnostic testing volumes continue to support market growth. Furthermore, the expansion of laboratory networks, improvements in automated and portable diagnostic technologies, and greater integration of digital data management systems have enhanced testing efficiency and turnaround times. Increasing investments in healthcare infrastructure, expanding access to diagnostic services, and the growing emphasis on preventive healthcare and routine screening further reinforce the leading position of clinical laboratories, enabling them to maintain the highest market share in the global point-of-care diagnostics market in 2025.

Asia Pacific set to witness robust growth through 2031.

The Asia Pacific is projected to register the highest growth in the global point-of-care diagnostics market, driven by the region's large and aging population, increasing prevalence of chronic and infectious diseases, and rising demand for rapid, accurate diagnostic testing. Additionally, improvements in healthcare infrastructure, increased healthcare spending, supportive government initiatives, and expanded access to primary healthcare are accelerating the adoption of point-of-care diagnostic solutions. The growing shift toward decentralized healthcare, including home-based testing and community care, along with ongoing advancements in portable, user-friendly diagnostic technologies, is expected to further drive market growth across the region.

Inquire Before Buying @https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=106829185

Top Companies in Point of Care Diagnostics Market:

The Top Companies in Point of Care Diagnostics Market include Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Siemens Healthineers AG (Germany), QuidelOrtho Corporation (US), bioMérieux SA (France), Werfen S.A. (Spain), Becton, Dickinson and Company (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (US), OraSure Technologies, Inc. (US), EKE Diagnostics (China), Trinity Biotech plc (Ireland), Grifols S.A. (Spain), Nova Biomedical Corporation (US), Sekisui Diagnostics, LLC (US), Trividia Health, Inc. (US), Sysmex Corporation (Japan), HemoCue AB (Sweden), and Bio-Rad Laboratories, Inc. (US).

Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting

Related Reports:

Coagulation Analyzer Market - Global Forecast to 2030

Home Healthcare Market - Global Forecast to 2030

PCR Technologies Market - Global Forecast to 2030

Molecular Diagnostics Market - Global Forecast to 2030

Point of Care Molecular Diagnostics Market - Global Forecast to 2030

About MarketsandMarkets

MarketsandMarkets has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore, which integrates research and provides ecosystem-wide visibility into revenue shifts.

MarketsandMarkets SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.

To find out more, visit www.MarketsandMarkets.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/point-of-care-diagnostics-market-worth-31-46-billion-by-2031--marketsandmarkets-302822598.html

© 2026 PR Newswire
SpaceX-Hype zu teuer – Diese 5 Aktien bieten bessere Chancen
Raumfahrt-Aktien gehören aktuell zu den heißesten Wetten an den Börsen. Spätestens mit dem spektakulären Börsengang von SpaceX ist der Sektor endgültig im Fokus der Anleger angekommen. Fantasien rund um Satellitenkommunikation, Rechenzentren im All und neue Geschäftsmodelle treiben die Kurse immer weiter nach oben.

Doch während die Begeisterung steigt, werden auch die Risiken größer. Viele Space-Start-ups sind inzwischen extrem hoch bewertet, arbeiten noch nicht profitabel und hängen stark von stetigem Kapitalzufluss ab. Schon kleine Rückschläge könnten die ambitionierten Wachstumspläne ins Wanken bringen.

Für Anleger, die vom Boom der Raumfahrt profitieren wollen, lohnt sich daher ein Perspektivwechsel. Statt auf überhitzte Pure Plays zu setzen, rücken etablierte Konzerne in den Fokus – Unternehmen mit jahrzehntelanger Erfahrung, stabilen Cashflows und engen Verbindungen zu Raumfahrtagenturen wie NASA und ESA.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau dieses Profil erfüllen: solide bewertet, operativ stark und bestens positioniert, um langfristig vom Space-Boom zu profitieren.

Jetzt den kostenlosen Report sichern – bevor der Markt die versteckten Gewinner entdeckt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.